Skip directly to content

Duchenne Dash Fundraiser - Why a team of Pfizer colleagues are cycling 'around the world' in 12 hours


Duchenne Muscular Dystrophy (DMD) is a severe type of muscle wasting disease affecting approximately one in 3,600 to 6,000 males at birth. By early teens many patients are unable to move around by themselves. If untreated DMD typically leads to death in the late teens, but improved care has seen increasing numbers of patients living into adulthood.1


The Duchenne Dash fundraiser, an event organised by the Duchenne UK charity, will be held on 3rd July at Goodwood Race Circuit. Participants will be cycling around the track for 12 hours in an attempt to collectively cycle the equivalent distance around the world (40,000km), in an effort to fundraise for this condition to support research efforts.

An incredible team of Pfizer colleagues have volunteered their time to participate in the Duchenne Dash and do all they can to contribute to such a worthy cause. Anthony, Dan, Eloise, Emma, Harriet, Jim, Dan and Owen have been training hard, clocking up the miles and aiming to raise the ambitious target of £16,000 for the charity.

The Duchenne Dash is all about raising money to help Duchenne UK meet their aim - to end Duchenne Muscular Dystrophy. For me this is totally aligned with our purpose of making breakthroughs that change patients' lives. It feels great to be part of the Pfizer team bringing our purpose to life to help fight this condition."

Jim Thompson, Senior Asset and Access Strategy Manager, Pfizer UK


Click here to make a donation

All funds raised will be donated to Duchenne UK.


Related articles:


Head of Rare Disease, Owen Marks discusses the development of gene therapy, and its potentially transformative impact on the rare disease community..


We are standing on the brink of a new era of innovation. But bringing this innovation to patients won’t be easy.


  1. National Center for Biotechnology Information. Adult care for Duchenne Muscular Dystrophy in the UK. Dec 2014.


PP-RDP-GBR-0899 / June 2021